ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 775

Identification of Candidate Items for Revised Classification Criteria for Systemic Lupus Erythematosus

Gabriela Schmajuk1, Bimba F. Hoyer2, Martin Aringer3, Sindhu R. Johnson4, Thomas Dorner5, David I. Daikh6 and SLE Classification Criteria Steering Committee, 1San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, 2Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, 3Rheumatology, Medicine III, University Clinical Center, Technical University Dresden, Dresden, Germany, 4Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, 5Charité – Universitätsmedizin, Berlin, Germany, 6Rheumatology, UCSF/VA Medical Center, San Francisco, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: SLE and classification criteria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

EULAR and ACR have
jointly funded a project to improve existing classification criteria for SLE;
this abstract reports on the early phase of this project.  Classification criteria
are being developed using multicriteria decision
analysis methods.  The goal of the initial phase of this project was to
generate a broad set of items potentially useful for the classification of SLE
and select a list of candidate items for use in forced-choice decision
analysis.  The aims were to include items that
encompass a broad spectrum of SLE, including patients whose disease is in the
early stage as well as those in the late stage, and that are in accordance with
criteria used for diagnosis of SLE in clinical practice.

Methods:

Items of potential utility for SLE classification criteria
were identified by a large international group of lupus clinicians in
independent exercises via response to online surveys.  In the first
survey, respondents were asked to evaluate existing ACR and SLICC
classification items and invited to propose additional, nontraditional clinical
items.  Submitted novel candidate items were summarized,
de-duplicated, and the number of total items reduced via a Delphi process.

Results:

135 individuals were invited to participate in each survey.
In the first survey, 120 (89% response rate) proposed a total of 196 unique
novel items for consideration.  Combining items with significant overlap
resulted in 159 items, including six that each contained one or more closely
related modifiers.   Nine items that are difficult to routinely
assess in current clinical practice (eg, “elevated
MCP1”) were removed from consideration.  The resulting 150 items were
evaluated in a second online survey.  Items achieving a threshold
significance score were retained for inclusion in SLE case scenarios to be
evaluated by lupus clinicians in the next phase of the project. 

Conclusion:

This approach to the development of SLE classification
criteria represents application of state-of-the-art methods for criteria
development.   The resulting core item list will be assessed for
discriminative characteristics in specific clinical scenarios to create a
weighted item list. The performance (sensitivity, specificity) of the weighted
item list will then be compared to existing classification criteria using data
collected from SLE patients and controls.

 

Table. Sample submitted, novel items for evaluation in new SLE classification criteria

General manifestations

Laboratory findings

Other organ manifestations

Constitutional symptoms (fevers, fatigue, weight loss)

Anti C1q antibody

Chillblain lupus

Family history of Autoimmune disease (first and second degree relatives)

Anti chromatin antibody

Cytoid bodies (retinal)

History of miscarriages

Anti thyroid antibodies

Diffuse alveolar hemorrhage

Persistent adenopathy

Complement fragments

Early cardiovascular disease

von Willebrand factor antigen

Interstitial lung disease

Libman-Sacks endocarditis

Lupus band test

Acute confusional state

Nasal ulcers

Pre-eclampsia

Persistent proteinuria (>0.5g/day)

Pulmonary arterial hypertension

 


Disclosure: G. Schmajuk, None; B. F. Hoyer, None; M. Aringer, None; S. R. Johnson, None; T. Dorner, None; D. I. Daikh, None.

To cite this abstract in AMA style:

Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Dorner T, Daikh DI. Identification of Candidate Items for Revised Classification Criteria for Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-of-candidate-items-for-revised-classification-criteria-for-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-candidate-items-for-revised-classification-criteria-for-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology